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Background
It is becoming increasingly clear that, during successful highly active antiretroviral therapy
(HAART), a proportion of treated patients develop opportunistic infections (OIs), referred to in
this setting as immune restoration disease (IRD). We examined the risk of developing IRD in
HAART-treated HIV-infected patients.
Methods
A retrospective study of a cohort including all 389 patients treated with HAART between 1 January
1998 and 31 May 2004 in our HIV unit was performed to evaluate the occurrence of and risk factors
for IRD during HAART. Baseline and follow-up values of CD4 T-cell counts and plasma viral loads
(pVLs) were compared to assess the success of HAART.
Results
During successful HAART (significant increase in CD4 T-cell counts and decrease in pVL), at least
one IRD episode occurred in 65 patients (16.7%). The median time to IRD was 4.6 months (range 2–
12 months). IRDs included dermatomal herpes zoster (26 patients), pulmonary tuberculosis (four
patients), tuberculous exudative pericarditis (two patients), tuberculous lymphadenitis (two patients),
cerebral toxoplasmosis (one patient), progressive multifocal leucoencephalopathy (PML) (one
patient), inflamed molluscum (one patient), inflamed Candida albicans angular cheilitis (three
patients), genital herpes simplex (two patients), tinea corporis (two patients), cytomegalovirus
(CMV) retinitis (two patients), CMV vitritis (one patient) and hepatitis B (three patients) or C (fifteen
patients). A baseline CD4 T-cell count below 100 cells/mL was shown to be the single predictor [odds
ratio (OR) 2.5, 95% confidence interval (CI) 0.9–6.4] of IRD, while a CD4 T-cell count increase to
4400 cells/mL, but not undetectable pVL, was a negative predictor of IRD (OR 0.3, 95% CI 0.1–0.8).
Conclusions
To avoid IRD in advanced patients, HAART should be initiated before the CD4 T-cell count falls
below 100 cells/mL.
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Introduction
The major advance in HIV disease treatment coincided with
the introduction of highly active antiretroviral therapy
(HAART) in 1996. HAART protocols comprised two
nucleoside reverse transcriptase inhibitors (NRTIs) and an
HIV protease inhibitor (PI), a rather complicated regimen,
but potent enough for complete and prolonged cessation of
viral replication to allow reconstitution of the immune
system. It has even been possible to achieve immune
recovery in terminally ill patients. An overall reduction in
late-stage complications of HIV infection, including death,
dramatically decreased the number of hospital admissions,
and an impressive improvement in the quality of life
became obvious.
Correspondence: Dr Olgica Djurković-Djaković, Institute for Medical
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However, although many patients continue to derive
substantial benefit from HAART after 5–6 years of
treatment, we are now facing the other side of the medal.
Cumulative long-term toxicity and the problem of the
development of HIV resistance to all drug classes are
threatening to jeopardize the treatment benefits. In
addition, over the past few years there have been growing
numbers of cases of opportunistic infections (OIs) in
patients on HAART. The common denominator in all these
cases was paradoxical symptomatic deterioration of
presumably pre-existing subclinical infections that be-
came symptomatic after the recovery of the immune
response and the consequent inflammatory response to
certain pathogens [1,2]. In this setting, numerous authors
described conditions including dermatomal herpes zoster,
tuberculous lymphadenitis, inflamed molluscum, in-
flamed Candida albicans angular cheilitis, genital herpes,
tinea corporis, hepatitis B or C virus (HBV or HCV)
infection, and even Toxoplasma gondii encephalitis, as
well as cryptococcal meningitis and progressive multi-
focal leucoencephalopathy (PML) [1–11], most commonly
referred to as immune restoration disease (IRD). While the
distinction between immunodeficiency-related OIs and
IRD is not clear, it is becoming accepted that the
appearance of clinical OIs at a time of restored immune
functions should be classified as IRD [12].
The majority of HIV-infected patients in Serbia have
advanced immunodeficiency on presentation. Even these
deeply immunosuppressed patients may achieve a good
virological and immunological response while on HAART,
as well as clinically apparent restoration of the immune
function. However, immune restoration may be associated
with the development of OIs, some of which may be
AIDS-defining and life-threatening [1–5]. These condi-
tions are referred to as IRD. We examined the risks of




A retrospective study of all 389 HIV-positive patients
treated with HAART at the HIV/AIDS Department of the
Institute of Infectious and Tropical Diseases in Belgrade
between 1 January 1998 and 31 May 2004 was conducted.
The patient series consisted of 39.7% females and 60.3%
males. The mean age was 41 10 years (range 16–78
years). All patients were diagnosed according to the 1993
revised CDC HIV classification system and expanded AIDS
surveillance definition for adolescents and adults.
Over half (55.3%) of the patients were pretreated with
monotherapy or dual regimens. HAART regimens were
defined as combinations of two or three NRTIs, with one or
two PIs (in 64% of all patients), or one nonnucleoside
reverse transcriptase inhibitor (NNRTI). Dual Pneumoeystis
carinii pneumonia (PCP) and toxoplasmosis primary
prophylaxis was withdrawn after patients achieved a
sustained immune response (CD4 cell count4200 cells/mL).
After commencing HAART, clinical evaluation was
performed at least once every 2 months.
Herpes zoster, inflamed molluscum, tinea corporis,
genital herpes, and angulus infectiosus were all diagnosed
by skin or mouth examination. For cerebral toxoplasmosis
and PML, clinical and neuroradiological presentations were
the clue to the diagnosis. T. gondii serology was routinely
performed. However, virological confirmation for PML,
such as cerebrospinal fluid JC virus (JCV) immunoglobulin
M (IgM) antibodies or PCR for JCV, was not available.
Cryptococcal menigitis was diagnosed according to the
clinical presentation and CSF findings, including Indian
ink stain and CSF culture. Tuberculosis was diagnosed on
the basis of clinical, radiographic and microbiological
confirmation. In patients who suffered coinfection of HIV
with HBV or HCV, the aggravation of hepatitis was defined
as an increase in alanine aminotransferase (ALT) activity of
at least 5-fold above the upper limit of the reference range.
Cytomegalovirus (CMV) retinitis relapse and vitritis were
diagnosed according to typical symptoms and fundoscopy
findings.
Laboratory methods
CD4 cell counts and viral loads were measured on
peripheral blood samples drawn at baseline (immediately
before HAART initiation) and every 4–6 months during
follow-up. CD4 T-cell counts were quantified by flow
cytometry. Plasma HIV-1 RNA loads were measured by a
quantitative reverse transcriptase PCR (Ultrasensitive
assay version 1.5, Roche Molecular Systems, Branchburg,
NJ, USA), which has a lower limit of detection of 50 copies/
mL (1.7 log10).
Statistics
All analyses were performed using an electronic database
organized with the SPSS (version 11.5) statistical package
(SPSS Inc., Chicago, IL, USA). CD4 cell count and plasma
viral load means were compared by one-way analysis of
variance (ANOVA). The level of significance was 0.05. The
association between IRD development and variables such
as basic and follow-up CD4 cell counts and plasma viral
loads, as well as other possibly related variables, was
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assessed using univariate and step-wise multivariate
regression models, and the Cox regression model. Results




Of the total of 389 patients, 87.3% had AIDS (CDC stages
A3–C3) before HAART was initiated. The baseline CD4 cell
count was below 100 cells/mL in 61.8% of patients, with a
mean of 108.2  92.8 cells/mL (range 0–450 cells/mL). The
median plasma viral load was 4.6 log copies/mL before
treatment.
Treatment effects
After a mean duration of treatment of 34.7  24.4 months,
the mean CD4 cell count in the whole patient series was
375  240 cells/mL, while 37.2% of patients reached a value
of above 400 cells/mL. In 76.8% of patients, the viral load
fell below 50 copies/mL (1.7 log). However, the most
desirable response to treatment, considered to be a rise in the
CD4 cell count of 400 cells/mL, along with a plasma viral
load of below 50 copies/mL, occurred in 44.6% of patients.
Subgroup of OI/IRD patients
Clinical findings
At least one IRD episode occurred in 65 patients (16.7%).
The median time on HAART to IRD was 4.6 months, with a
range of 2–12 months. These included episodes of
dermatomal herpes zoster (26 patients), pulmonary
tuberculosis (four patients), tuberculous exudative peri-
carditis (two patients), tuberculous lymphadenitis (two
patients), cerebral toxoplasmosis (one patient), PML (one
patient), inflamed molluscum (one patient), inflamed C.
albicans angular cheilitis (three patients), genital herpes
simplex (two patients), tinea corporis (two patients), CMV
retinitis (two patients), CMV vitritis (one patient) and HBV
(three patients) or HCV (fifteen patients) infection. In the
patients with tuberculosis, cerebral toxoplasmosis and
cryptococcosis as manifestations of IRD, symptoms and
signs occurred after early initiation of HAART, before
withdrawal of antimicrobial therapy. In the case of
inflamed molluscum, aggravation of skin lesions also
occurred soon after HAART initiation. Genital herpes,
angular cheilitis, and herpes zoster and warts occurred de
novo. Aggravation of hepatitis was associated with
clinical disease in only two cases, both of HCV infection,
of which one female patient with HCV-induced cirrhosis
died of liver failure. In a patient who experienced immune
recovery vitritis, the sight-threatening vitreomacular
traction syndrome and detachment of the retina occurred,
which did not resolve during 2 years of successful HAART.
Response to HAART: laboratory findings
In the subgroup of IRD patients, the mean CD4 cell count
during HAART rose from 106  104 to 337  219 cells/mL.
The median plasma viral load simultaneously decreased by
41 log copies/mL (from the initial 4.6 to 2.1  0.8 log10
copies/mL), with 80% of patients reaching undetectable
viraemia. However, the median CD4 count increase and the
median plasma viral load decrease were similar to those in
the non-IRD patients (P5 0.6 and P5 0.7, respectively).
IRD risk assessment
Multivariate logistic regression analysis showed that, of all
the examined factors, including age over 40 years, gender,
AIDS-related OIs prior to HAART, pretreatment with mono
and/or dual antiretroviral regimens, and baseline CD4
count below 100 cells/mL, the latter was the only predictor
of IRD (OR 2.5, 95% CI 0.9–6.4). However, the Cox
regression model showed that achievement of a rise in
the CD4 cell count to above 400 cells/mL, but not
undetectable viraemia, was a negative predictor of IRD
(OR 0.3, 95% CI 0.1–0.8).
IRD management
Anti-infective therapy was used to treat IRD when needed,
to which all patients responded well, with the exception of
one fatal case of HCV infection, as described above. During
such treatment, HAART was temporarily withdrawn,
mostly because of potential unfavourable drug–drug
interactions. Corticosteroids or other anti-inflammatory
drugs were not used to treat IRD. After IRD resolution,
patients continued HAART successfully.
Discussion
Numerous studies have shown that HAART corrects many
of the immune defects caused by HIV infection [12–14].
Restored pathogen-specific immune responses may result
in regression or prevention of OIs [13–16]. However, the
restoration of pathogen-specific immune responses may
also cause inflammation of tissues infected by the
pathogen, known as IRD [1–12]. Thus, the major question
in the setting of HAART-treated HIV disease is whether a
clinical OI is immunodeficiency-related or an IRD,
because the appearance of OIs among HIV-infected
patients on HAART always raises the concern of possible
HAART failure. Attempts at solving this problem resulted
in the first proposal of criteria for the diagnosis of IRD
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[12], which include, in addition to precise clinical
findings, success of HAART, where virological success
is considered a major criterion and an increased blood
CD4 cell count a minor criterion.
In our patient series, all 65 OI episodes fulfilled the
above criteria for the clinical OI to be defined as IRD, as
significant immunological and virological improvement
was documented. Hence, the incidence of IRD in our series
was 16.7%. This is in sharp contrast with the study of
Michelet et al. [6], who reported that 68% of patients
exhibited one or more disease episodes after successful
HAART. One reason for the lower incidence in our study
may be that our series included patients observed over a
rather long period of over 6 years; at the beginning of this
period (1998), the IRD syndrome was not well known,
so some OIs as IRDs may have been overlooked because
symptoms had not been searched for, while some
infections of possible IRD origin had been considered
HIV-related OIs. However, our results are not in disagree-
ment with those of French et al. [3], who reported that 25%
of HAART-treated patients developed IRD episodes after
commencing HAART, all related to pre-existing
subclinical infections with opportunistic pathogens. The
IRD episodes were more common in patients with a
baseline CD4 count of less than 50 cells/mL [3]. We also
showed that a low baseline CD4 count represents a risk
factor for IRD. These data indicate the need for earlier
HAART initiation.
In conclusion, with the wide use of HAART in AIDS
patients, the frequency of IRD may be expected to increase.
IRD should particularly be considered during the first 12
months following HAART initiation. We showed that the
likelihood of developing IRD was elevated in those who
commenced HAART at an advanced stage of HIV disease
and, conversely, extremely low in patients who achieved
CD4 cell count rises to above 400 cells/mL. Thus, any effort
to decrease the incidence of IRD should include HAART
initiation before the disease has reached an advanced stage,
i.e. before the CD4 cell counts have fallen below 100 cells/
mL. In patients with OIs as a consequence of HIV-induced
immunodeficiency, it seems wise to complete antimicrobial
therapy before commencing HAART.
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